Treats Major Depressive Disorder. ANDA 206993, held by Cadila Pharms Ltd. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 206993 (Fluoxetine Hydrochloride), held by Cadila Pharms Ltd, was first approved by FDA on May 23, 2019, with 3 approved supplements and 0 published complete response letters.
Fluoxetine capsules are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 23, 2019 | Original application | Approved | None posted |
| Fluoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Fluoxetine Hydrochloride | Rx |
| Fluoxetine HydrochlorideEQ 20MG BASE · capsule;oral | Fluoxetine Hydrochloride | Rx |
| Fluoxetine HydrochlorideEQ 40MG BASE · capsule;oral | Fluoxetine Hydrochloride | Rx |
| Feb 12, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 12, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 23, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 23, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters